The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 18)
Improved Biomarkers and Clinical Outcome Measures, 2018
Cognitive-driven Activities of Daily Living Impairment as a Predictor for Parkinson's Disease Dementia
Mild cognitive impairment in Parkinson's disease (PD-MCI) is the highest risk factor for Parkinson's disease dementia (PDD). The core feature for differentiating PDD from PD-MCI is the loss of the ability to perform activities of daily living (ADL). First signs of ADL impairment can be observed in a subgroup of patients with PD-MCI, suggesting that mild ADL impairment in PD-MCI mi...
Researchers: Inga Liepelt-Scarfone, PhD
Inflammation Biomarkers Program, 2018
Previous studies have shown that the body's immune response is involved in Parkinson's disease. This includes inflammation in the brain as well as systemic inflammation. One recent study has found that T lymphocytes, a type of white blood cell, recognize parts of the alpha-synuclein protein. This protein becomes abnormally aggregated in Parkinson's disease and is thought to cause ...
Researchers: Kirsten M. Scott, MD, MPhil
Improved Biomarkers and Clinical Outcome Measures, 2015
Current methods to evaluate motor impairments in Parkinson's disease rely on subjective examinations. Our team seeks to develop an objective assessment of motor deficits by monitoring natural interactions with a keyboard (on a computer or smart device). This approach provides a window to how the brain behaves during typical daily use of these devices (e.g. writin...
Researchers: Martha L. Gray, PhD
LRRK2 Role in Idiopathic Parkinson's Disease, 2014
Genetic variability in the LRRK2 gene is recognized as one of the most common cause of Parkinson's disease (PD) mainly in the Caucasian, African-Arab, Ashkenazi Jewish and East Asian populations. There is a complete lack of knowledge regarding the role of LRRK2-dependent PD in the Indian population. To understand the role of the LRRK2 locus and its prevalence in the Indian popu...
Therapeutic Pipeline Program, 2014
Tryptophan-2,3-dioxygenase (TDO) is a key enzyme in the tryptophan degradation pathway. In a Parkinson's disease (PD) model, TDO was identified as a potential therapeutic target. Scientists at the Netherlands Translational Research Center (NTRC) have developed an innovative TDO screening assay (laboratory experiment) and have applied this assay to identify inhibi...
Researchers: Rogier C. Buijsman, PhD